Advertisement

Topics

ABEC and WuXi Biologics Company Profile

06:22 EDT 25th June 2018 | BioPortfolio

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.


News Articles [633 Associated News Articles listed on BioPortfolio]

WuXi Biologics to Install Largest SUB from ABEC

Selects 4,000L Custom Single Run disposable bioreactors for new commercial manufacturing facility in Wuxi

WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufact...

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United ...

WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing Read ...

WuXi Biologics kicks off $20m ADC build in China

WuXi Biologics has started building its antibody-drug conjugate (ADC) centre in Wuxi City, China, where it will offer biologics conjugate services for clients.

WuXi Biologics Invests $60 Million in Another New Plant -- In Singapore This Time

WuXi Biologics will spend $60 million to build a biologics CDMO plant in Singapore. The facility will be WuXi Biologics' tenth manufacturing plant globally and the third new facility it has announced ...

WuXi Biologics to Build New Biologics Plant Near Boston -- Announces Four New Facilities (a $792 Million Investment) in Two Months

WuXi Biologics will invest $60 million to build a state-of-the-art biologics CDMO operation in the greater Boston area, the fourth new manufacturing project WuXi has announced in the last two months. ...

WuXi Biologics to Build $20 Million ADC Facility in Wuxi City

WuXi Biologics has begun construction of a $20 million state-of-the-art integrated biologics conjugate R&D/CDMO center in Wuxi city, China. The company said the 6,000 square meter facility, which ...

WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang

WuXi Biologics will build a $240 million CDMO facility in Shijiazhuang, the capital of China's northern Hebei province. The new facility is an addition to WuXi Biologics' existing CDMO facilities in S...

PubMed Articles [113 Associated PubMed Articles listed on BioPortfolio]

Biologics for pityriasis rubra pilaris treatment: a review of the literature.

Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease, often refractory to conventional therapies. The off-label use of biologics, such as anti-TNF, -IL-12/IL-23, -IL-17 ag...

Facilitated recruitment of mesenchymal stromal cells by bone marrow concentrate and platelet rich plasma.

Biologics containing growth factors are frequently used to enhance healing after musculoskeletal injuries. One mechanism of action is thought to be though the ability of biologics to induce homing and...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases.

Inflammatory Bowel Disease (IBD) is an inflammatory disorder of the gastrointestinal tract that can necessitate hospitalization and the use of expensive biologics. Models predicting these intervention...

Clinical Trials [75 Associated Clinical Trials listed on BioPortfolio]

Serological Screening of Gastric Cancer in Wuxi Region

The purpose of this study is to determine whether detection of pepsinogen Ⅰand Ⅱ combined with Helicobacter pylori antibody, so-called ABC method , is fit on gastric cancer screening i...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Companies [264 Associated Companies listed on BioPortfolio]

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

ABEC Incorporated

ABEC designs and manufactures custom designed, turn-key manufacturing equipment for the pharmaceutical, bio-tech, animal health and food industries. Our products include fermentors, bio-reactors, clea...

WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused co...

WuXi PharmaTech, Ltd.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused com...

WuXi AppTec

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along wi...

More Information about "ABEC and WuXi Biologics" on BioPortfolio

We have published hundreds of ABEC and WuXi Biologics news stories on BioPortfolio along with dozens of ABEC and WuXi Biologics Clinical Trials and PubMed Articles about ABEC and WuXi Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ABEC and WuXi Biologics Companies in our database. You can also find out about relevant ABEC and WuXi Biologics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...


Corporate Database Quicklinks



Searches Linking to this Company Record